CD69 and neoplasm: This observed change in the PD-1/CD69 ratio could indicate a shift in the balance of activation and PD-1 expression towards the former, which could be beneficial in the context of tumor immunology, particularly in conjunction with reduced PD-L1 expression on tumor cells (17).